Comparison of salvage therapies for isolated para-aortic lymph node recurrence in patients with uterine cervical cancer after definitive treatment

Table 1 Patient characteristics

Variable		No.	%
Histopathology	Squamous cell carcinoma	40	80
	Adenocarcinoma	7	14
	Adenosquamous carcinoma	1	2
	Neuroendcrine carcinoma	1	2
	Carcinoma with rhabdoid feature	1	2
Initial FIGO stage	I	11	22
	II	24	48
	III	10	20
	IV	5	10
Initial treatment	Surgery with PORT	23	46
	Surgery without PORT	5	10
	CCRT	17	34
	RT alone	5	10
Age at the recurrence (year)	Median (range)	57 (26–84)
Serum SCC at the recurrence	Positive	26	43
	Negative	17	28
	Missing	18	30
Serum CEA at the recurrence	Positive	26	43
	Negative	17	28
	Missing	18	30
Time interval between completion of initial treatment and PALN recurrence (month)	Median (range)	10 (1–91)
Maximum size of PALN recurrence (mm)	Median (range)	17 (8–60)
Number of recurrent PALN	1–2	24	48
Number of recurrent PALN	≥ 3	26	52
Treatment for PALN recurrence	RT alone	18	36
	CCRT	7	14
	Surgery	3	6
	Chemotherapy	17	34
	BSC	5	10

*Abbreviations: FIGO International Federation of Gynecology and Obstetrics, Port Post-operative radiation therapy, serum SCC Serum squamous cell carcinoma antigen, serum CEA Serum carcinoembryonic antigen, CCRT Concurrent chemoradiation therapy, RT Radiation therapy, PALN Para-aortic lymph nodes, BSC Best supportive care

ISSN: 1748-717X